195 related articles for article (PubMed ID: 37331786)
1. Theranostics and Patient-Specific Dosimetry.
Bednarz B
Semin Radiat Oncol; 2023 Jul; 33(3):317-326. PubMed ID: 37331786
[TBL] [Abstract][Full Text] [Related]
2. Voxel-Level Dosimetry for Combined Iodine 131 Radiopharmaceutical Therapy and External Beam Radiation Therapy Treatment Paradigms for Head and Neck Cancer.
Adam DP; Grudzinski JJ; Marsh IR; Hill PM; Cho SY; Bradshaw TJ; Longcor J; Burr A; Bruce JY; Harari PM; Bednarz BP
Int J Radiat Oncol Biol Phys; 2024 Jul; 119(4):1275-1284. PubMed ID: 38367914
[TBL] [Abstract][Full Text] [Related]
3. Dosimetry for radiopharmaceutical therapy.
Sgouros G; Hobbs RF
Semin Nucl Med; 2014 May; 44(3):172-8. PubMed ID: 24832581
[TBL] [Abstract][Full Text] [Related]
4. Radiopharmaceutical therapy in the era of precision medicine.
Sgouros G; Goldenberg DM
Eur J Cancer; 2014 Sep; 50(13):2360-3. PubMed ID: 24953565
[TBL] [Abstract][Full Text] [Related]
5. Validation of Monte Carlo
Adam DP; Grudzinski JJ; Bormett I; Cox BL; Marsh IR; Bradshaw TJ; Harari PM; Bednarz BP
Med Phys; 2022 Aug; 49(8):5491-5503. PubMed ID: 35607296
[TBL] [Abstract][Full Text] [Related]
6. A Framework for Patient-Centered Pathways of Care for Radiopharmaceutical Therapy: An ASTRO Consensus Document.
Buatti JM; Pryma DA; Kiess AP; Mailman J; Ennis RD; Menda Y; White GA; Pandit-Taskar N
Int J Radiat Oncol Biol Phys; 2021 Mar; 109(4):913-922. PubMed ID: 33249143
[TBL] [Abstract][Full Text] [Related]
7. Technical note: Impact of dose voxel kernel (DVK) values on dosimetry estimates in
Danieli R; Pistone D; Tranel J; Botta F; Uribe-Munoz C; Raspanti D; Salvat F; Wilderman SJ; Bardiès M; Amato E; Dewaraja YK; Cremonesi M
Med Phys; 2024 Jan; 51(1):522-532. PubMed ID: 37712869
[TBL] [Abstract][Full Text] [Related]
8. A Pipeline for Automated Voxel Dosimetry: Application in Patients with Multi-SPECT/CT Imaging After
Dewaraja YK; Mirando DM; Peterson AB; Niedbala J; Millet JD; Mikell JK; Frey KA; Wong KK; Wilderman SJ; Nelson AS
J Nucl Med; 2022 Nov; 63(11):1665-1672. PubMed ID: 35422445
[TBL] [Abstract][Full Text] [Related]
9. Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice.
Pandit-Taskar N; Iravani A; Lee D; Jacene H; Pryma D; Hope T; Saboury B; Capala J; Wahl RL
J Nucl Med; 2021 Dec; 62(Suppl 3):60S-72S. PubMed ID: 34857623
[TBL] [Abstract][Full Text] [Related]
10. Overcoming Barriers to Radiopharmaceutical Therapy (RPT): An Overview From the NRG-NCI Working Group on Dosimetry of Radiopharmaceutical Therapy.
Divgi C; Carrasquillo JA; Meredith R; Seo Y; Frey EC; Bolch WE; Zimmerman BE; Akabani G; Jacobson DA; Brown B; Davern SM; Hobbs RF; Humm J; Moros EG; Morse D; Papineni R; Zanzonico P; Benedict SH; Sgouros G
Int J Radiat Oncol Biol Phys; 2021 Mar; 109(4):905-912. PubMed ID: 33309909
[TBL] [Abstract][Full Text] [Related]
11. Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns.
Sgouros G; Dewaraja YK; Escorcia F; Graves SA; Hope TA; Iravani A; Pandit-Taskar N; Saboury B; James SS; Zanzonico PB
J Nucl Med; 2021 Dec; 62(Suppl 3):12S-22S. PubMed ID: 34857617
[TBL] [Abstract][Full Text] [Related]
12. Individualized Dosimetry for Theranostics: Necessary, Nice to Have, or Counterproductive?
Eberlein U; Cremonesi M; Lassmann M
J Nucl Med; 2017 Sep; 58(Suppl 2):97S-103S. PubMed ID: 28864620
[TBL] [Abstract][Full Text] [Related]
13. Current Status of Radiopharmaceutical Therapy.
St James S; Bednarz B; Benedict S; Buchsbaum JC; Dewaraja Y; Frey E; Hobbs R; Grudzinski J; Roncali E; Sgouros G; Capala J; Xiao Y
Int J Radiat Oncol Biol Phys; 2021 Mar; 109(4):891-901. PubMed ID: 32805300
[TBL] [Abstract][Full Text] [Related]
14. Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs.
Miller C; Rousseau J; Ramogida CF; Celler A; Rahmim A; Uribe CF
Theranostics; 2022; 12(1):232-259. PubMed ID: 34987643
[TBL] [Abstract][Full Text] [Related]
15. Theranostic Surrogacy of [
Kim SB; Lee MS; Song IH; Park HS; Kim SE
Mol Pharm; 2023 Jul; 20(7):3460-3470. PubMed ID: 37294909
[TBL] [Abstract][Full Text] [Related]
16. A single-institution experience with
George SC; Tolakanahalli R; Aguirre S; Kim TP; Samuel EJJ; Mishra V
Front Oncol; 2024; 14():1331266. PubMed ID: 38469241
[TBL] [Abstract][Full Text] [Related]
17. The Case for Dosimetry in Alpha-Emitter Therapy.
Sgouros G
J Med Imaging Radiat Sci; 2019 Dec; 50(4 Suppl 1):S45-S46. PubMed ID: 31537496
[TBL] [Abstract][Full Text] [Related]
18. Dosimetry for Optimized, Personalized Radiopharmaceutical Therapy.
Graves SA; Hobbs RF
Semin Radiat Oncol; 2021 Jan; 31(1):37-44. PubMed ID: 33246635
[TBL] [Abstract][Full Text] [Related]
19. Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer.
Sgouros G; Hobbs RF; Atkins FB; Van Nostrand D; Ladenson PW; Wahl RL
Eur J Nucl Med Mol Imaging; 2011 May; 38 Suppl 1(Suppl 1):S41-7. PubMed ID: 21484384
[TBL] [Abstract][Full Text] [Related]
20. Linear Boltzmann equation solver for voxel-level dosimetry in radiopharmaceutical therapy: Comparison with Monte Carlo and kernel convolution.
Kayal G; Van B; Andl G; Tu C; Wareing T; Wilderman S; Mikell J; Dewaraja YK
Med Phys; 2024 Mar; ():. PubMed ID: 38436493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
